Auris Medical Holding AG (NASDAQ:EARS) dropped 7.4% on Tuesday . The company traded as low as $0.25 and last traded at $0.25. Approximately 2,305,524 shares were traded during trading, an increase of 49% from the average daily volume of 1,547,469 shares. The stock had previously closed at $0.27.
Separately, ValuEngine raised Auris Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The firm has a market capitalization of $15.60, a PE ratio of -0.38 and a beta of 0.46. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of -14.04.
About Auris Medical
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.